Impact & Expertise


  • Biopharma R&D in China: Making Bets Pay Off

  • Michael Choy, Rachel Lee , John Wong
  • November 2011
  • With most major biopharma companies now active in China, their emphasis has begun to shift from participating to outperforming. They are doing more with their R&D investments by externalizing a broader range of activities, creating local networks to tap new sources of innovation, and pursuing new-drug discovery.

  • Read more on bcg.perspectives

Search for a Publication

  • * Please select an Industry
  • * Please select a Capability
  • * Please select Practice Area Type
  • Go

Keyword Search:

Enter a keyword here to search our publications database.

Winning in a Slow-Growth Economy

Surviving and thriving in the downturn is the theme of our Collateral Damage series, which includes some practical steps that companies need to take now to secure their future. READ

BCG Offices

GlobeBCG has more than 80 offices around the world. Learn about our global presence. GO

The Premier Thought-Leadership Resource

BCG.Perspectives siteExplore the latest cutting-edge thinking on business and management